Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.78 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.78 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.75 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.75 |
| ▸ | ACE | P12821 | 1/20 | 0.75 |
| ▸ | HTR2A | P28223 | 1/20 | 0.75 |
| ▸ | FAP | Q12884 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7902672 | 1.00 | DPP4 (0.78) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL14267898 | 1.00 | DPP4 (0.78) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL13317131 | 0.92 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL12767537 | 0.89 | DPP4 (0.81) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL15362765 | 0.88 | DPP4 (0.62) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL15362761 | 0.88 | DPP4 (0.62) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL1709088 | 0.88 | DPP4 (0.62) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL5487338 | 0.87 | DPP4 (0.74) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL5935863 | 0.87 | DPP4 (0.74) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL5935871 | 0.87 | DPP4 (0.74) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203550-A1 | USE OF STEREOSELECTIVE TRANSAMINASE IN ASYMMETRIC SYNTHESIS OF CHIRAL AMINE | ABIOCHEM BIOTECHNOLOGY CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230142248-A1 | METHOD FOR RACEMIC PREPARATION OF CHIRAL B-AMINO ACIDS AND DERIVATIVES THEREOF | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-9938282-B2 | Expedient synthesis of sitagliptin | STEREOKEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180086765-A1 | NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME | KYUNG DONG PHARM. CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| US-20170183351-A1 | EXPEDIENT SYNTHESIS OF SITAGLIPTIN | STEREOKEM, INC. | 2017-06-29 | — | — | US | disclosed |
| US-9587229-B2 | Immobilized transaminases and process for making and using immobilized transaminase | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9587229-B2 | Immobilized transaminases and process for making and using immobilized transaminase | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9409912-B2 | Process for the preparation of sitagliptin phosphate | CADILA HEALTHCARE LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-9187419-B2 | Intermediates of sitagliptin and preparation process thereof | ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD. (CN) | 2015-11-17 | — | — | US | disclosed |
| US-20150087834-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE | CADILA HEALTHCARE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-7485732-B2 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK & CO., INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7390835-B2 | Aralkyl amines as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1756064-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20080076805-A1 | Acyclic Hydrazides as Cannabinoid Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| US-7326708-B2 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070281941-A1 | Amorphous Form of a Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor | MERCK SHARP & DOHME LLC | 2007-12-06 | — | — | US | disclosed |
| US-20070099884-A1 | Combination therapy for the treatment of diabetes | MERCK & CO., INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070088058-A1 | 3-(1(S)(4-chlorobenzyl)-2(S)-((2-hydroxy-2-methyl-1-phenylpropyl)amino)propyl)-benzonitrile; obesity; potentiation; antagonists | MERCK SHARP & DOHME CORP. | 2007-04-19 | — | — | US | disclosed |
| US-20070032517-A1 | Substituted naphthyridinone derivatives | MERCK SHARP & DOHME CORP. | 2007-02-08 | — | — | US | disclosed |
| US-20070021430-A1 | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor | MERCK & CO., INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281941-A1 | Amorphous Form of a Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 4/4885DPP9 5/4885 |
| US-20180086765-A1 | NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 4/4885DPP9 3/4885 |
| US-20080076805-A1 | Acyclic Hydrazides as Cannabinoid Receptor Modulators | CNR1, CNR2, FAAH | DPP4 1050/4885DPP8 2315/4885DPP9 1603/4885 |
| US-20150087834-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE | DPP4, DPP9, SI | DPP4 1/4885DPP8 9/4885DPP9 2/4885 |
| US-20070099884-A1 | Combination therapy for the treatment of diabetes | GPR119, FABP4, IAPP | DPP4 5/4885DPP8 35/4885DPP9 45/4885 |
| US-20070021430-A1 | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 4/4885DPP9 5/4885 |
| US-20070088058-A1 | 3-(1(S)(4-chlorobenzyl)-2(S)-((2-hydroxy-2-methyl-1-phenylpropyl)amino)propyl)-benzonitrile; obesity; potentiation; antagonists | CNR2, CNR1, CHRNA4 | DPP4 1734/4885DPP8 3701/4885DPP9 2096/4885 |
| US-20170183351-A1 | EXPEDIENT SYNTHESIS OF SITAGLIPTIN | DPP4, DPP7, DPP8 | DPP4 1/4885DPP8 3/4885DPP9 4/4885 |
| US-20070032517-A1 | Substituted naphthyridinone derivatives | CNR1, CNR2, MAG | DPP4 2758/4885DPP8 2453/4885DPP9 1851/4885 |
| US-20230142248-A1 | METHOD FOR RACEMIC PREPARATION OF CHIRAL B-AMINO ACIDS AND DERIVATIVES THEREOF | GLP1R, SRR, GIPR | DPP4 7/4885DPP8 19/4885DPP9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.